Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 11, Novembre 2013
Page(s) 1018 - 1025
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132911019
Publié en ligne 20 novembre 2013
  1. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003 ; 44 : 33–40. [PubMed] [Google Scholar]
  2. Bellahcene A, Castronovo V, Ogbureke KU, et al. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs) : multifunctional proteins in cancer. Nat Rev Cancer 2008 ; 8 : 212–226. [CrossRef] [PubMed] [Google Scholar]
  3. Staines KA, MacRae VE, Farquharson C. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 2012 ; 214 : 241–255. [CrossRef] [PubMed] [Google Scholar]
  4. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006 ; 17 : 463–474. [CrossRef] [PubMed] [Google Scholar]
  5. Hanahan D, Weinberg RA. Hallmarks of cancer : the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
  6. Sung V, Stubbs JT, 3rd, Fisher L, et al. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998 ; 176 : 482–494. [CrossRef] [PubMed] [Google Scholar]
  7. Lee JL, Wang MJ, Sudhir PR, et al. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms : OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007 ; 67 : 2089–2097. [CrossRef] [PubMed] [Google Scholar]
  8. Pecheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. Faseb J 2002 ; 16 : 1266–1268. [PubMed] [Google Scholar]
  9. von Marschall Z, Fisher LW. Dentin matrix protein-1 isoforms promote differential cell attachment and migration. J Biol Chem 2008 ; 283 : 32730–32740. [CrossRef] [PubMed] [Google Scholar]
  10. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006 ; 66 : 883–888. [CrossRef] [PubMed] [Google Scholar]
  11. Courter D, Cao H, Kwok S, et al. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 2010 ; 5 : e9633. [CrossRef] [PubMed] [Google Scholar]
  12. Ahmed M, Behera R, Chakraborty G, et al. Osteopontin : a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011 ; 15 : 1113–1126. [CrossRef] [PubMed] [Google Scholar]
  13. Kayed H, Kleeff J, Keleg S, et al. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. Cancer Lett 2007 ; 245 : 171–183. [CrossRef] [PubMed] [Google Scholar]
  14. Joshi R, Tawfik A, Edeh N, et al. Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2. PLoS One 2010 ; 5 : e13974. [CrossRef] [PubMed] [Google Scholar]
  15. Rangaswami H, Kundu GC. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep 2007 ; 18 : 909–915. [PubMed] [Google Scholar]
  16. Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration : novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005 ; 22 : 663–673. [CrossRef] [PubMed] [Google Scholar]
  17. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004 ; 21 : 515–523. [CrossRef] [PubMed] [Google Scholar]
  18. Yan W, Qian C, Zhao P, et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 2010 ; 12 : 765–775. [CrossRef] [PubMed] [Google Scholar]
  19. Sharp JA, Waltham M, Williams ED, et al. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 2004 ; 21 : 19–29. [CrossRef] [PubMed] [Google Scholar]
  20. Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007 ; 26 : 6361–6371. [CrossRef] [PubMed] [Google Scholar]
  21. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 2005 ; 4 : 33. [CrossRef] [PubMed] [Google Scholar]
  22. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J 2004 ; 18 : 734–736. [PubMed] [Google Scholar]
  23. Fisher LW, Jain A, aTayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 2004 ; 10: 8501–8511. [CrossRef] [PubMed] [Google Scholar]
  24. Ogbureke KU, Nikitakis NG, Warburton G, et al. Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol 2007 ; 43 : 920–932. [CrossRef] [PubMed] [Google Scholar]
  25. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004 ; 96 : 956–965. [CrossRef] [PubMed] [Google Scholar]
  26. Karadag A, Fedarko NS, Fisher LW. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 2005 ; 65 : 11545–11552. [CrossRef] [PubMed] [Google Scholar]
  27. Fedarko NS, Fohr B, Robey PG, et al. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000 ; 275 : 16666–16672. [CrossRef] [PubMed] [Google Scholar]
  28. Jain A, Karadag A, Fohr B, et al. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H’s cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 2002 ; 277 : 13700–13708. [CrossRef] [PubMed] [Google Scholar]
  29. Fidler IJ. The pathogenesis of cancer metastasis : the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003 ; 3 : 453–458. [CrossRef] [PubMed] [Google Scholar]
  30. Wai PY, Kuo PC. Osteopontin : regulation in tumor metastasis. Cancer Metastasis Rev 2008 ; 27 : 103–118. [CrossRef] [PubMed] [Google Scholar]
  31. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996 ; 13 : 97–104. [PubMed] [Google Scholar]
  32. Adwan H, Bauerle TJ, Berger MR. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 2004 ; 11 : 109–120. [CrossRef] [PubMed] [Google Scholar]
  33. Mandelin J, Lin EC, Hu DD, et al. Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin. Cancer 2009 ; 115 : 1753–1764. [CrossRef] [PubMed] [Google Scholar]
  34. Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994 ; 54 : 2823–2826. [PubMed] [Google Scholar]
  35. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998 ; 90 : 1000–1008. [CrossRef] [PubMed] [Google Scholar]
  36. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003 ; 3 : 537–549. [CrossRef] [PubMed] [Google Scholar]
  37. Zhang JH, Tang J, Wang J, et al. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003 ; 23 : 1043–1048. [PubMed] [Google Scholar]
  38. Zhang JH, Wang J, Tang J, et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 2004 ; 24 : 1361–1368. [PubMed] [Google Scholar]
  39. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells : a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999 ; 39 : 246–261. [CrossRef] [PubMed] [Google Scholar]
  40. Bellahcene A, Bachelier R, Detry C, et al. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007 ; 101 : 135–148. [CrossRef] [PubMed] [Google Scholar]
  41. Barnes GL, Javed A, Waller SM, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003 ; 63 : 2631–2637. [PubMed] [Google Scholar]
  42. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994 ; 264 : 569–571. [CrossRef] [PubMed] [Google Scholar]
  43. Wang Y, Yan W, Lu X, et al. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 2011 ; 90 : 642–648. [CrossRef] [PubMed] [Google Scholar]
  44. Cui R, Takahashi F, Ohashi R, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007 ; 57 : 302–310. [CrossRef] [PubMed] [Google Scholar]
  45. Dai J, Peng L, Fan K, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009 ; 28 : 3412–3422. [CrossRef] [PubMed] [Google Scholar]
  46. Blasberg JD, Goparaju CM, Pass HI, Donington JS. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2010 ; 139 : 1587–1593. [CrossRef] [PubMed] [Google Scholar]
  47. Bellahcene A, Bonjean K, Fohr B, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 2000 ; 86 : 885–891. [CrossRef] [PubMed] [Google Scholar]
  48. Pirotte S, Lamour V, Lambert V, et al. Dentin matrix protein 1 induces membrane expression of VE-cadherin on endothelial cells and inhibits VEGF-induced angiogenesis by blocking VEGFR-2 phosphorylation. Blood 2011 ; 117 : 2515–2526. [CrossRef] [PubMed] [Google Scholar]
  49. Bucciarelli E, Sidoni A, Bellezza G, et al. Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro. Breast Cancer Res Treat 2007 ; 105 : 95–104. [CrossRef] [PubMed] [Google Scholar]
  50. Chabas D. L’ostéopontine, une molécule aux multiples facettes. Med Sci (Paris) 2005 ; 21 : 832–838. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  51. Orian-Rousseau V. CD44, un régulateur de la croissance et de l’invasion cellulaire. Med Sci (Paris) 2003 ; 19 : 405–407. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  52. Bidard FC, Poupon MF. Biologie du processus métastatique. Med Sci (Paris) 2012 ; 28 : 89–95. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.